Download

Download Full Text (572 KB)

Document Type

Poster

Description

• PMS/PMDD symptoms affect many women's emotional and physical wellbeing.

• SSRIs, progesterone, and sepranolone are luteal phase treatment options.

• Studies were all peer-reviewed, including randomized control trials or a meta-analysis.

• SSRIs are a consistent primary treatment for symptom alleviation especially cognitive symptoms. SSRIs are the current mainstay, recommended for luteal phase treatment of PMS/PMDD.

• SSRIs, including citalopram, sertraline, escitalopram, and fluoxetine, were examined to determine their efficacy in relieving mood-related symptoms such as irritability, anxiety, and depression during the luteal phase.

• Data on progesterone treatment in the luteal phase is inconclusive. • Allopregnanolone levels and sepranolone treatment research are currently delivering a new understanding of hormonal mechanisms in PMS/PMDD.

• Sepranolone remains in trial and is not yet available for clinical use.

Department

Physician Assistant Studies

Degree Name

Master of Physician Assistant Studies (MPAS)

Date of Work

2024

First Advisor

Solberg, Julie

Publication Date

Summer 2024

Keywords

Premenstrual Dysphoric Disorder, Selective Serotonin Reuptake Inhibitors, Progesterone, Fluoxetine, Premenstrual Syndrome, Sepranolone, Allopregnanolone, Luteal Phase, Premenstrual.

Disciplines

Medicine and Health Sciences

Premenstrual Dysmorphic Disorder/Premenstrual Syndrome Luteal Phase Treatment

Share

COinS